Fusion protein and use thereof

US12351604B2 · kind B2 · utility

Assignees

• SHANXI JINBO BIO-PHARMACEUTICAL CO., LTD. · CN
• FUDAN UNIVERSITY · CN

Inventors

• Lu Lu · San Diego, US
• Shibo Jiang · Floral Park, US
• Zezhong Liu · Shanghai, CN
• Jie Zhou · Mason, US
• Qian Wang · Santa Clara, US
• Xia Yang · Chengdu, CN
• Zhenrui He · Taiyuan, CN

Key dates

• Filing date: May 15, 2023
• Grant date: Jul 8, 2025
• Expiry date: May 15, 2043

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2770/20034
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided are a fusion protein and use thereof. Provided is a fusion protein, comprising a trimerization block and an immunogenic block which are connected by a linker, wherein the trimerization block comprises one or more of repeat units set forth in SEQ ID NO. 1; the immunogenic block is an immunogenic protein of a pathogen, for example, being selected from a coronavirus RBD block, an HIV membrane protein or an influenza virus hemagglutinin protein, and immunogenic fragments thereof. Compared with an immunogen monomer, the trimer can generate a higher neutralizing antibody level, does not induce a strong antibody against the trimerization block in a human body, and can promote the immune response of the organism to be focused on the immunogenic block.